

2019 Future of Drug Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2C77A89F6FDEN.html>

Date: February 2019

Pages: 150

Price: US\$ 2,199.00 (Single User License)

ID: 2C77A89F6FDEN

Abstracts

The global demand for Drug Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Drug Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Drug Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Drug Addiction Report Description-

The 2019 pipeline study on Drug Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Drug Addiction pipeline compounds.

The Drug Addiction pipeline guide presents information on all active drugs currently being developed for Drug Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Drug Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Drug Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Drug Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Drug Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Drug Addiction pipeline report includes-

An overview of Drug Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Drug Addiction pipeline

Company wise list of Drug Addiction pipeline

Mechanism of Action wise Drug Addiction pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Drug Addiction pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Drug Addiction pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Drug Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL DRUG ADDICTION PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Drug Addiction Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Drug Addiction pipeline, H1- 2019
- 3.5 Mechanism of Action wise Drug Addiction Pipeline Candidates

4 ADDEX THERAPEUTICS LTD DRUG ADDICTION PIPELINE DETAILS

- 4.1 Addex Therapeutics Ltd Business Profile
- 4.2 Addex Therapeutics Ltd Drug Addiction Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AELIS FARMA SAS DRUG ADDICTION PIPELINE DETAILS

- 5.1 Aelis Farma SAS Business Profile
- 5.2 Aelis Farma SAS Drug Addiction Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMYGDALA NEUROSCIENCES INC DRUG ADDICTION PIPELINE DETAILS

- 6.1 Amygdala Neurosciences Inc Business Profile
- 6.2 Amygdala Neurosciences Inc Drug Addiction Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 APHIOS CORP DRUG ADDICTION PIPELINE DETAILS

- 7.1 Aphios Corp Business Profile
- 7.2 Aphios Corp Drug Addiction Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 ASTRAEA THERAPEUTICS LLC DRUG ADDICTION PIPELINE DETAILS

- 8.1 Astraea Therapeutics LLC Business Profile
- 8.2 Astraea Therapeutics LLC Drug Addiction Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIOCORRX INC DRUG ADDICTION PIPELINE DETAILS

- 9.1 BioCorRx Inc Business Profile
- 9.2 BioCorRx Inc Drug Addiction Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CAMINO PHARMA LLC DRUG ADDICTION PIPELINE DETAILS

- 10.1 Camino Pharma LLC Business Profile
- 10.2 Camino Pharma LLC Drug Addiction Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CHARLESTON LABORATORIES INC DRUG ADDICTION PIPELINE DETAILS

- 11.1 Charleston Laboratories Inc Business Profile
- 11.2 Charleston Laboratories Inc Drug Addiction Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CHIESI FARMACEUTICI SPA DRUG ADDICTION PIPELINE DETAILS

- 12.1 Chiesi Farmaceutici SpA Business Profile
- 12.2 Chiesi Farmaceutici SpA Drug Addiction Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 CONSEGNA PHARMA INC DRUG ADDICTION PIPELINE DETAILS

- 13.1 Consegna Pharma Inc Business Profile
- 13.2 Consegna Pharma Inc Drug Addiction Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 CUREMARK LLC DRUG ADDICTION PIPELINE DETAILS

14.1 Curemark LLC Business Profile

14.2 Curemark LLC Drug Addiction Drug Details

14.3 Drug Snapshot

14.3.1 Originator

14.3.2 Collaborator/Co-Developer

14.3.3 Route of Administration

14.3.4 Orphan Drug/Fast Track/Special Designation

14.3.5 Geography

14.3.6 Type of Molecular Entity

14.3.7 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15 DAYA DRUG DISCOVERIES INC DRUG ADDICTION PIPELINE DETAILS

15.1 Daya Drug Discoveries Inc Business Profile

15.2 Daya Drug Discoveries Inc Drug Addiction Drug Details

15.3 Drug Snapshot

15.3.1 Originator

15.3.2 Collaborator/Co-Developer

15.3.3 Route of Administration

15.3.4 Orphan Drug/Fast Track/Special Designation

15.3.5 Geography

15.3.6 Type of Molecular Entity

15.3.7 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 EGALET CORP DRUG ADDICTION PIPELINE DETAILS

16.1 Egalet Corp Business Profile

- 16.2 Egalet Corp Drug Addiction Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 EMBERA NEUROTHERAPEUTICS INC DRUG ADDICTION PIPELINE DETAILS

- 17.1 Embera NeuroTherapeutics Inc Business Profile
- 17.2 Embera NeuroTherapeutics Inc Drug Addiction Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 ENCEPHEAL THERAPEUTICS INC DRUG ADDICTION PIPELINE DETAILS

- 18.1 EncepHeal Therapeutics Inc Business Profile
- 18.2 EncepHeal Therapeutics Inc Drug Addiction Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration

- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 EOLAS THERAPEUTICS INC DRUG ADDICTION PIPELINE DETAILS

- 19.1 Eolas Therapeutics Inc Business Profile
- 19.2 Eolas Therapeutics Inc Drug Addiction Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 F. HOFFMANN-LA ROCHE LTD DRUG ADDICTION PIPELINE DETAILS

- 20.1 F. Hoffmann-La Roche Ltd Business Profile
- 20.2 F. Hoffmann-La Roche Ltd Drug Addiction Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 FORESEE PHARMACEUTICALS CO LTD DRUG ADDICTION PIPELINE DETAILS

- 21.1 Foresee Pharmaceuticals Co Ltd Business Profile
- 21.2 Foresee Pharmaceuticals Co Ltd Drug Addiction Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 HEPTARES THERAPEUTICS LTD DRUG ADDICTION PIPELINE DETAILS

- 22.1 Heptares Therapeutics Ltd Business Profile
- 22.2 Heptares Therapeutics Ltd Drug Addiction Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 IMV INC DRUG ADDICTION PIPELINE DETAILS

- 23.1 IMV Inc Business Profile
- 23.2 IMV Inc Drug Addiction Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 INTERVEXION THERAPEUTICS LLC DRUG ADDICTION PIPELINE DETAILS

- 24.1 InterveXion Therapeutics LLC Business Profile
- 24.2 InterveXion Therapeutics LLC Drug Addiction Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 INTERVEXION THERAPEUTICS LLC DRUG ADDICTION PIPELINE DETAILS

- 25.1 InterveXion Therapeutics LLC Business Profile
- 25.2 InterveXion Therapeutics LLC Drug Addiction Drug Details
- 25.3 Drug Snapshot

- 25.3.1 Originator
- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 INTRA-CELLULAR THERAPIES INC DRUG ADDICTION PIPELINE DETAILS

- 26.1 Intra-Cellular Therapies Inc Business Profile
- 26.2 Intra-Cellular Therapies Inc Drug Addiction Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 JOHNSON & JOHNSON DRUG ADDICTION PIPELINE DETAILS

- 27.1 Johnson & Johnson Business Profile
- 27.2 Johnson & Johnson Drug Addiction Drug Details
- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation
 - 27.3.5 Geography

- 27.3.6 Type of Molecular Entity
- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 KDAC THERAPEUTICS INC DRUG ADDICTION PIPELINE DETAILS

- 28.1 Kdac Therapeutics Inc Business Profile
- 28.2 Kdac Therapeutics Inc Drug Addiction Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer
 - 28.3.3 Route of Administration
 - 28.3.4 Orphan Drug/Fast Track/Special Designation
 - 28.3.5 Geography
 - 28.3.6 Type of Molecular Entity
 - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 KYORIN PHARMACEUTICAL CO LTD DRUG ADDICTION PIPELINE DETAILS

- 29.1 Kyorin Pharmaceutical Co Ltd Business Profile
- 29.2 Kyorin Pharmaceutical Co Ltd Drug Addiction Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation
 - 29.3.5 Geography
 - 29.3.6 Type of Molecular Entity
 - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details

29.7 Latest Drug Developments

30 KYOWA HAKKO KIRIN CO LTD DRUG ADDICTION PIPELINE DETAILS

- 30.1 Kyowa Hakko Kirin Co Ltd Business Profile
- 30.2 Kyowa Hakko Kirin Co Ltd Drug Addiction Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography
 - 30.3.6 Type of Molecular Entity
 - 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 MAKSCIENTIFIC LLC DRUG ADDICTION PIPELINE DETAILS

- 31.1 MAKScientific LLC Business Profile
- 31.2 MAKScientific LLC Drug Addiction Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 MAYO CLINIC DRUG ADDICTION PIPELINE DETAILS

- 32.1 Mayo Clinic Business Profile

32.2 Mayo Clinic Drug Addiction Drug Details

32.3 Drug Snapshot

32.3.1 Originator

32.3.2 Collaborator/Co-Developer

32.3.3 Route of Administration

32.3.4 Orphan Drug/Fast Track/Special Designation

32.3.5 Geography

32.3.6 Type of Molecular Entity

32.3.7 Current Status

32.4 Drug Overview

32.5 Drug Mechanism of Action

32.6 Clinical/Pre-clinical Trial Details

32.7 Latest Drug Developments

33 MELKIN PHARMACEUTICALS DRUG ADDICTION PIPELINE DETAILS

33.1 MEIkin Pharmaceuticals Business Profile

33.2 MEIkin Pharmaceuticals Drug Addiction Drug Details

33.3 Drug Snapshot

33.3.1 Originator

33.3.2 Collaborator/Co-Developer

33.3.3 Route of Administration

33.3.4 Orphan Drug/Fast Track/Special Designation

33.3.5 Geography

33.3.6 Type of Molecular Entity

33.3.7 Current Status

33.4 Drug Overview

33.5 Drug Mechanism of Action

33.6 Clinical/Pre-clinical Trial Details

33.7 Latest Drug Developments

34 NLS PHARMA GROUP DRUG ADDICTION PIPELINE DETAILS

34.1 NLS Pharma Group Business Profile

34.2 NLS Pharma Group Drug Addiction Drug Details

34.3 Drug Snapshot

34.3.1 Originator

34.3.2 Collaborator/Co-Developer

34.3.3 Route of Administration

- 34.3.4 Orphan Drug/Fast Track/Special Designation
- 34.3.5 Geography
- 34.3.6 Type of Molecular Entity
- 34.3.7 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

35 OMEROS CORP DRUG ADDICTION PIPELINE DETAILS

- 35.1 Omeros Corp Business Profile
- 35.2 Omeros Corp Drug Addiction Drug Details
- 35.3 Drug Snapshot
 - 35.3.1 Originator
 - 35.3.2 Collaborator/Co-Developer
 - 35.3.3 Route of Administration
 - 35.3.4 Orphan Drug/Fast Track/Special Designation
 - 35.3.5 Geography
 - 35.3.6 Type of Molecular Entity
 - 35.3.7 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

36 OREXIGEN THERAPEUTICS INC DRUG ADDICTION PIPELINE DETAILS

- 36.1 Orexigen Therapeutics Inc Business Profile
- 36.2 Orexigen Therapeutics Inc Drug Addiction Drug Details
- 36.3 Drug Snapshot
 - 36.3.1 Originator
 - 36.3.2 Collaborator/Co-Developer
 - 36.3.3 Route of Administration
 - 36.3.4 Orphan Drug/Fast Track/Special Designation
 - 36.3.5 Geography
 - 36.3.6 Type of Molecular Entity
 - 36.3.7 Current Status
- 36.4 Drug Overview

- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

37 PHOENIX PHARMALABS DRUG ADDICTION PIPELINE DETAILS

- 37.1 Phoenix PharmaLabs Business Profile
- 37.2 Phoenix PharmaLabs Drug Addiction Drug Details
- 37.3 Drug Snapshot
 - 37.3.1 Originator
 - 37.3.2 Collaborator/Co-Developer
 - 37.3.3 Route of Administration
 - 37.3.4 Orphan Drug/Fast Track/Special Designation
 - 37.3.5 Geography
 - 37.3.6 Type of Molecular Entity
 - 37.3.7 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

38 SANIONA AB DRUG ADDICTION PIPELINE DETAILS

- 38.1 Saniona AB Business Profile
- 38.2 Saniona AB Drug Addiction Drug Details
- 38.3 Drug Snapshot
 - 38.3.1 Originator
 - 38.3.2 Collaborator/Co-Developer
 - 38.3.3 Route of Administration
 - 38.3.4 Orphan Drug/Fast Track/Special Designation
 - 38.3.5 Geography
 - 38.3.6 Type of Molecular Entity
 - 38.3.7 Current Status
- 38.4 Drug Overview
- 38.5 Drug Mechanism of Action
- 38.6 Clinical/Pre-clinical Trial Details
- 38.7 Latest Drug Developments

39 SAVANT HWP INC DRUG ADDICTION PIPELINE DETAILS

- 39.1 Savant HWP Inc Business Profile
- 39.2 Savant HWP Inc Drug Addiction Drug Details
- 39.3 Drug Snapshot
 - 39.3.1 Originator
 - 39.3.2 Collaborator/Co-Developer
 - 39.3.3 Route of Administration
 - 39.3.4 Orphan Drug/Fast Track/Special Designation
 - 39.3.5 Geography
 - 39.3.6 Type of Molecular Entity
 - 39.3.7 Current Status
- 39.4 Drug Overview
- 39.5 Drug Mechanism of Action
- 39.6 Clinical/Pre-clinical Trial Details
- 39.7 Latest Drug Developments

40 SEROPEUTICS LLC DRUG ADDICTION PIPELINE DETAILS

- 40.1 Seropeutics LLC Business Profile
- 40.2 Seropeutics LLC Drug Addiction Drug Details
- 40.3 Drug Snapshot
 - 40.3.1 Originator
 - 40.3.2 Collaborator/Co-Developer
 - 40.3.3 Route of Administration
 - 40.3.4 Orphan Drug/Fast Track/Special Designation
 - 40.3.5 Geography
 - 40.3.6 Type of Molecular Entity
 - 40.3.7 Current Status
- 40.4 Drug Overview
- 40.5 Drug Mechanism of Action
- 40.6 Clinical/Pre-clinical Trial Details
- 40.7 Latest Drug Developments

41 SPRINGWORKS THERAPEUTICS LLC DRUG ADDICTION PIPELINE DETAILS

- 41.1 SpringWorks Therapeutics LLC Business Profile
- 41.2 SpringWorks Therapeutics LLC Drug Addiction Drug Details
- 41.3 Drug Snapshot
 - 41.3.1 Originator

- 41.3.2 Collaborator/Co-Developer
- 41.3.3 Route of Administration
- 41.3.4 Orphan Drug/Fast Track/Special Designation
- 41.3.5 Geography
- 41.3.6 Type of Molecular Entity
- 41.3.7 Current Status
- 41.4 Drug Overview
- 41.5 Drug Mechanism of Action
- 41.6 Clinical/Pre-clinical Trial Details
- 41.7 Latest Drug Developments

42 ZYNERBA PHARMACEUTICALS INC DRUG ADDICTION PIPELINE DETAILS

- 42.1 Zynerba Pharmaceuticals Inc Business Profile
- 42.2 Zynerba Pharmaceuticals Inc Drug Addiction Drug Details
- 42.3 Drug Snapshot
 - 42.3.1 Originator
 - 42.3.2 Collaborator/Co-Developer
 - 42.3.3 Route of Administration
 - 42.3.4 Orphan Drug/Fast Track/Special Designation
 - 42.3.5 Geography
 - 42.3.6 Type of Molecular Entity
 - 42.3.7 Current Status
- 42.4 Drug Overview
- 42.5 Drug Mechanism of Action
- 42.6 Clinical/Pre-clinical Trial Details
- 42.7 Latest Drug Developments

43. LATEST DRUG ADDICTION DRUG PIPELINE DEVELOPMENTS, 2019

44. APPENDIX

- 44.1 About Us
- 44.2 Sources and Methodology
- 44.3 Contact Information

I would like to order

Product name: 2019 Future of Drug Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2C77A89F6FDEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C77A89F6FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

